IVA - Inventiva S.A.

3.62
0.100   2.762%

Share volume: 11,802
Last Updated: 05-09-2025
Pharmaceutical Products/Pharmaceutical Preparations: -0.09%

PREVIOUS CLOSE
CHG
CHG%
$3.52
0.10
0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
8%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 20%
Performance
5 Days
0.70%
1 Month
10.04%
3 Months
14.54%
6 Months
14.54%
1 Year
14.54%
2 Year
14.54%
Key data
Stock price
$3.62
P/E Ratio 
N/A
DAY RANGE
$3.49 - $3.62
EPS 
N/A
52 WEEK RANGE
$2.67 - $4.05
52 WEEK CHANGE
$14.54
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
09-24-2025
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$20,410
AVERAGE 30 VOLUME 
$20,185
Company detail
CEO: Frédéric Cren
Region: US
Website: inventivapharma.com
Employees: 100
IPO year: 2020
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Inventiva S.A. focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH.

Recent news
loading